Replies to post #17553 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA’s 9/30/17 pro forma cash balance was $389.1M—a decrease of $75.1M relative to the $464.2M pro forma cash balance on 6/30/17 (#msg-133589207). The large magnitude of the quarterly decrease derives, in part, from forfeiture of the $35M cash bond MNTA filed with the US District Court pertaining to the Lovenox patent case.

The $389.1M pro forma figure above consists of: $442.5M of current assets on the 9/30/17 balance sheet (https://www.sec.gov/Archives/edgar/data/1235010/000123501017000040/mnta3q201710-q.htm#sDF67CD42769F594DB196535A3DF935EB ); $4.3M of marketable securities designated as long-term (e.g. T-bonds with a maturity >1yr); less $57.7M of liabilities (not counting the current and non-current “deferred revenue” lines on the balance sheet, which are accounting artifacts rather than true liabilities).